ABSTRACT
The category of acute myeloid leukemia not otherwise specified (AML NOS) encompasses cases that do not fulfill criteria for inclusion in one of the AML entities, including AML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, or therapy-related AML.
1 AML NOS is a heterogeneous disease with regard to cytomorphology, cytogenetic or molecular genetic characteristics, and prognosis, whereas other categories of AML have their own distinct clinical attributes. Therefore, mutational analysis and cytogenetic studies are highly recommended for cases of AML NOS and may offer more prognostic significance than the morphologic subtypes. 1 According to recent National Comprehensive Cancer Network (NCCN) guidelines, intermediate-risk cytogenetics include normal karyotype, +8 alone, t(9;11), and others nondefined. 2 Consequently, almost all cases of AML NOS have to be classified as an intermediate cytogenetic risk group. Thus, mutational analysis will have a more imperative role to delineate prognostications than cytogenetic analysis in patients with AML NOS.
Runt-related transcription factor 1 (RUNX1) acts as a key regulator of hematopoiesis through the regulation of various hematopoietic genes. Differentiation of myeloid progenitor cells to granulocytes requires RUNX1, which is the most frequent target of chromosomal translocation associated with human leukemia. If a chimeric RUNX1 gene inactivates RUNX1 function to cause leukemia, then loss-of-function RUNX1 mutations may also cause myeloid leukemia. 3 Indeed, previous studies revealed that somatic mutations in the RUNX1 gene have been identified in a substantial proportion of patients with de novo AML and were linked to distinct clinical and prognostic characteristics. Briefly, RUNX1-mutated AML is associated with the male sex, an older age, a FrenchAmerican-British (FAB) subtype M0, MLL-partial tandem duplication (PTD), IDH and ASXL1 mutations, and trisomy 13 and is inversely correlated with NPM1 and CEBPA mutations. [4] [5] [6] [7] [8] [9] In addition, patients with RUNX1 mutations generally showed adverse clinical outcomes. [4] [5] [6] [7] [8] [9] For these reasons, AML with mutated RUNX1 is considered a new provisional entity in the upcoming revision of World Health Organization (WHO) classifications of myeloid neoplasms and acute leukemia. 10 Herein, we report on the frequency and clinicopathologic correlations of RUNX1 mutations, focusing on patients with AML NOS in which the mutational status could be much more important than any other AML subcategories. We have also reviewed and summarized results of previous studies reporting on RUNX1-mutated AML.
Materials and Methods

Patients
From January 2008 to December 2015, a total of 219 consecutive patients with AML NOS according to the 2008 WHO classification were studied at Asan Medical Center, Seoul, South Korea. These patients had cryopreserved bone marrow or blood cells available for molecular analysis. Cytogenetic risk stratification was based on recent NCCN guidelines. 2 Cases were studied for the presence of recurrent fusion genes, including RUNX1-RUNX1T1, CBFB-MYH11, PML-RARA, MLLT3-MLL, and BCR-ABL1, principally by reverse transcriptase polymerase chain reaction (PCR), and for gene mutations, including FLT3-internal tandem duplication (ITD), NPM1 mutations, CEBPA mutations, and MLL-PTD performed as previously described. [11] [12] [13] [14] Immunophenotypic evaluation was performed using a multiparametric flow cytometer, and the expression of an antigen was considered positive when this was expressed in 20% or more of the tested cells. Cytogenetic analysis was performed using conventional G-banding techniques. The standard induction regimen of our center included 7 days of cytarabine Patients who achieved complete remission (CR) after one or two courses of induction chemotherapy were scheduled to receive two to six cycles of high-dose cytarabine-based consolidation chemotherapy. Further therapeutic modalities were undertaken at the attending physician's discretion and according to the cytogenetic risk group, age, performance status, comorbidities, and the availability of an appropriate donor. This study was approved by the Institutional Review Board of the Asan Medical Center and was performed in accordance with the Declaration of Helsinki.
Molecular Analysis of the RUNX1 Gene
Genomic DNA was extracted from bone marrow or peripheral blood using standard methods. The entire coding region of the RUNX1 gene was amplified with the use of six separate PCRs and subsequently analyzed by direct sequencing according to the protocol in a previous study with several modifications. 15 The primers used were as follows: forward, 5ʹ-GCTGTTTGCAGGGTCCTAA-3ʹ and reverse, 5ʹ-CCTGTCCTCCCACCACCCTC-3ʹ for exon 1; forward, 5ʹ-cattgctattcctctgcaacc-3ʹ and reverse, 5ʹ-CCGAGTTTCTAGGGATTCCA-3ʹ for exon 2; forward, 5ʹ-AAATTCCGGGAGTGTTGTCA-3ʹ and reverse, 5ʹ-GCAACTTTTTGGCTTTTACGG-3ʹ for exon 3; forward, 5ʹ-GGGAGAGAGAGGGGAAAGAC-3ʹ and reverse, 5ʹ-TCTGAGCATCAAGGGGAAAC-3ʹ for exon 4; forward, 5ʹ-GAACAAGGGCCACTCATTTC-3ʹ and reverse, 5ʹ-GGGCATGGGACTCAGAGTAG-3ʹ for exon 5; and forward, 5ʹ-CCGCAACCTCCTACT-CACTT-3ʹ and reverse, 5ʹ-CCTGACCTACAGC-GAGATCC-3ʹ for exon 6. PCR conditions consisted of an initial denaturation step at 94°C for 5 minutes, followed by 35 cycles of 94°C for 45 seconds, 57°C for 30 seconds, and 72°C for 30 seconds, and a final extension at 72°C for 10 minutes. Purified PCR fragments were sequenced using forward and reverse primers. Sequences were compared with the NM_001001890.2 reference sequence from GenBank (Bethesda, MD). If the peak height ratio of a mutant to a wild-type peak was below 1.0, it was considered a "heterozygous mutant." If a RUNX1 wild-type peak was not detectable, it was considered a "homozygous mutant."
Statistical Analyses
Differences in the distributions of continuous values between categories were analyzed using the Wilcoxon ranksum test. Patient groups with nominal values were compared using the χ 2 test. Overall survival (OS) was calculated from the date of diagnosis to date of death (uncensored) or the last follow-up (censored). Relapse-free survival (RFS) was calculated from the date CR was achieved to the date of death (uncensored) or the last follow-up (censored). OS and RFS were plotted using Kaplan-Meier curves and compared by a log-rank test. P values less than .05 were considered statistically significant. Statistical analyses were performed using MedCalc program version 14.12.0 (MedCalc Software, Acacialaan, Belgium).
Results
Frequency and Types of RUNX1 Mutations
Three single-nucleotide polymorphisms of RUNX1 were detected in 22 patients. RUNX1 mutations were identified in 33 (15.1%) of 219 patients. Thirty (90.9%) mutation-positive patients had heterozygous mutations, whereas only three (9.1%) patients had homozygous mutations. Because two mutations (p.R139* and p.R319fs) were shared by two patients each, a total of 31 types of RUNX1 mutations were detected in this study. as a result of an insertion, deletion, or both. The other half were single-nucleotide substitutions, including 13 (41.9%) missense mutations and two (6.5%) nonsense mutations. Single-nucleotide substitutions were almost exclusively detected in the RHD, whereas frameshift mutations were scattered throughout the entire region of the RUNX1 gene. All mutations in the TAD were frameshift mutations ❚Figure 1❚.
Cytogenetic, Molecular, and Immunophenotypic Features of RUNX1-Mutated Cases
For the 33 patients with RUNX1 mutations, the two most common karyotypes were a normal karyotype (NK; 48.5%) and trisomy 8 (15.2%). The frequency of NK was lower in patients with RUNX1 mutations compared with patients with a RUNX1 wild type, although a significant difference was not observed. Sex chromosome loss was detected more frequently in patients with RUNX1 mutations (9.1%) than with RUNX1 wild type (0.5%; P = .007). Three of four sex chromosome losses in total patients included a loss of Y. There was no significant difference in the frequency of the RUNX1 mutation when only males were evaluated (P = .139). The frequencies of other cytogenetic abnormalities were not significantly different, except for tendencies toward a higher frequency of -20/del(20) (P = .089) in patients with RUNX1 mutations. FLT3-ITD was detected in nine (27.3%) of 33 patients with RUNX1 mutations and equally distributed between patients with a RUNX1 mutation and a RUNX1 wild type.
In contrast, NPM1 and CEBPA mutations were mutually exclusive of RUNX1 mutations ❚Table 1❚. For patients with NK AML (n = 132), 16 (12.1%) had a RUNX1 mutation. The frequencies of FLT3-ITD, NPM1, and CEBPA mutations were 34.4% (45/131), 32.2% (38/118), and 9.7% (11/113), respectively, among patients with NK AML. Furthermore, of the patients with NK AML and no RUNX1 mutation, the frequencies of FLT3-ITD, NPM1, and CEBPA mutations were 32.2% (37/115), 36.9% (38/103), and 11.1% (11/99), respectively. Twenty-nine (87.9%) patients with AML NOS and RUNX1 mutations were positive for both CD34 and HLA-DR, indicating early hematopoietic-associated antigens. Furthermore, 13 (39.4%) patients were negative for CD15 in addition to CD34+/HLA-DR+, suggesting poor myeloid maturation. Cross-lineage expression was detected in eight (24.2%) patients with RUNX1 mutations, including CD56 (n = 3), CD7 (n = 2), TdT (n = 2), and CD2/CD7 (n = 1). ❚Table 2❚ summarizes types of mutations, associations with cytogenetics and FLT3 mutations, and immunophenotypic features in patients with RUNX1 mutations.
Clinical Features and Outcomes of RUNX1-Mutated Cases
For the 33 patients with a RUNX1 mutation, 22 (66.7%) were male, and the median age was 61 years (range, 12-80 years). Median blood cell measurements were a WBC count of 8.7 × 10 9 /L, hemoglobin of 8.3 g/dL, and a platelet count of 52 × 10 9 /L. The median blast count was 57.0% (range, 21.6%-88.4%). Of the FAB subtypes, FAB ❚Figure 1❚ Distribution and types of different RUNX1 mutations. Different colors indicate different types of the mutation on the linear structure of the RUNX1 protein (NP_001001890.1): frameshift in violet, missense in blue, and nonsense in red. Arrows indicate the mutations shared by two patients each (p.R139* and p.R319fs). Arrowhead indicates two mutations sharing the same region of amino acids (p.D171Y and p.D171G). The following table shows the frequency according to the position and type of the mutation. aa, amino acid; RHD, Runt homology domain; TAD, transactivation domain.
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AJCP / Original article M2 (33.3%) was the most common, followed by FAB M1 (30.3%), FAB M4 (15.2%), and FAB M0 (12.1%). The distribution of RUNX1 mutations according to sex and age was not significantly different, although the median age and the frequency of males among patients with a RUNX1 mutation were slightly higher than those of patients with the RUNX1 wild type. The median platelet count was significantly lower in patients with a RUNX1 mutation compared with that of patients with a RUNX1 wild type (P = .013). However, differences with respect to WBC count, hemoglobin level, and bone marrow blast percentage were not observed among patients with a RUNX1 mutation or wild-type gene. A significant difference was not observed for FAB subtypes, although the frequency of the FAB M0 subtype was higher in patients with a RUNX1 mutation compared with patients with the RUNX1 wild type (Table 1) .
Of the 203 patients who underwent conventional induction chemotherapy for more than one cycle, the CR rate was significantly inferior in patients with a RUNX1 mutation (15/ The distribution of cytogenetic abnormalities may overlap each other. For example, the patient showing "49,XX,+8,+13,+18 [8] /46,XX [12] " was categorized as having "+8", "+13"; "other trisomies or additions"; and "two or three abnormalities."
You et al / RUNX1 Mutations in aML nos patients with AML. [4] [5] [6] [7] [8] [9] Since one study 6 was merged into a larger study 9 performed by the same authors, we eventually reviewed and present a summary of five studies as well as the present study ❚Table 3❚. Bearing in mind that every study was of different patients, the overall frequency of a RUNX1 mutation in patients with AML was 13.6%. The mean age of patients with a RUNX1 mutation was approximately 66 years, with males predominating. Among patients with a RUNX1 mutation, the overall frequency of the FAB M0 subtype was 17%, reaching 26.3% in a study on the noncomplex karyotype AML. 5 In contrast, patients did not show an FAB M7 morphology. Even though we cannot directly compare between NCCN and European Leukemia Net risk distributions, most patients with a RUNX1 mutation were confined to an intermediate-risk group in both risk stratification systems. Slightly more than half (55.9%) of patients with RUNX1 mutations showed NK, and 13.4% of patients with NK AML had an RUNX1 mutation. Trisomy 8 (9.3%) was the most common cytogenetic abnormality, followed by trisomy 13 (8.4%), -7/del(7q) (7.4%), and a complex karyotype (5.8%). Frameshift mutations (47.7%) were the most common type of mutation, with more than half (57.9%) of mutations located in the RHD. 
Discussion
The RUNX1 gene encodes the α-subunit of the core binding factor, a transcriptional factor widely expressed This patient was previously diagnosed with primary myelofibrosis and subsequently underwent hematopoietic cell transplantation.
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AJCP / Original article in hematopoietic cells that is indispensable for the establishment of definitive hematopoiesis. In studies in mice, the function of the RUNX1 gene in adult-type hematopoiesis is inhibitory; it is also thought to negatively regulate myeloid precursors since RUNX1 knockout mice show expanded bone marrow stem cell fractions. 16 Thus, RUNX1 has important roles in hematopoiesis, and its functional dysregulation leads to leukemia. 3 A RUNX1 mutation was detected in approximately 10% of unsorted AML patients and was the sixth most common mutation, preceded by FLT3 (28%), NPM1 (27%), DNMT3A (26%), IDH1 or IDH2 (20%), and NRAS or KRAS (12%). 17 That frequency of 10% was recently reconfirmed in a large-sized study on 2,439 patients with unselected, newly diagnosed AML. 9 However, the frequency of RUNX1 mutations found has been variable, depending on patients' characteristics. For instance, the frequency decreased to 5% in patients younger than 60 years, 18 which reflects the relative preponderance of RUNX1 mutations in older patients. [4] [5] [6] [7] [8] [9] In contrast, the frequency became higher than 10% in patient groups in which the intermediate cytogenetic risk group was dominant. 5, 7, 8 This may also be the case in the present study, because most patients with AML NOS are categorized as having an intermediate cytogenetic risk, irrespective of risk stratification system. Exceptionally, Schnittger et al 5 reported 32.7% of RUNX1 mutations in patients with AML harboring a noncomplex karyotype. However, this high percentage could have resulted from a selection bias since the authors stressed that patients were selected and that only those with available clinical follow-up data were preferentially analyzed in that study. Generally, however, RUNX1 mutations are detected in approximately 5% to 15% (mean, 10%) of patients with AML. In terms of mutational frequencies, the NPM1 mutation is clearly lower in this study than in others. However, recent studies from Korea and Japan have demonstrated that the frequencies of the NPM1 mutation among patients with NK AML were 36.8%, 19 44.1%, 20 and 40.3%, 21 respectively. This suggests an ethnic variation in the frequency of the NPM1 mutation, and this, at least in part, may be one of the reasons for a lower frequency of NPM1 mutation found in the present study than previous studies principally performed in Western countries.
Previous studies as well as this study have demonstrated that over half of RUNX1 mutations clustered in the RHD of the RUNX1 gene sequence. In addition, missense mutations clustered in the RHD, whereas frameshift mutations were scattered across the whole gene sequence. The RHD is a DNA binding domain. Core-binding factor subunit β (CBFB) increases RHD binding to DNA by stabilizing a particular conformation of the RHD. Therefore, many missense mutations in the RHD involving residues at the DNA binding interface affect DNA binding. On the other hand, mutations C-terminal to the RHD, primarily frameshift or nonsense mutations, result in the production of proteins lacking all or part of the TAD. 22 Tsai et al 23 observed that most RUNX1 mutants had reduced abilities in DNA binding, CBFB heterodimerization, and C-FMS gene induction and revealed that low RUNX1 activity was an independent predictor for secondary leukemia-free survival in patients with myelodysplastic syndrome (MDS). This indicates that biologic activity might be more critical in predicting patients' outcome than the mutational status or types of RUNX1, at least in MDS. Further study will be needed to confirm the significance of the remaining activities of mutant RUNX1 in patients with AML.
RUNX1 mutations showed a relatively high frequency of coexisting mutations, such as FLT3-ITD, ASXL1, TET2, DNMT3A, IDH2, and MLL-PTD, in patients with AML. In contrast, previous studies and our study repeatedly showed an inverse correlation between RUNX1 mutations and NPM1 or CEBPA mutations. MLL-PTD has a higher incidence within the NK AML group or cases with trisomy 11. 24 Therefore, an absence of trisomy 11 in RUNX1-mutated cases in this study can be an explanation, at least in part, for why the frequency of MLL-PTD seems to be lower in our patients compared with those in other studies. However, a previous study conducted on patients with NK AML demonstrated that MLL-PTD was found in only 6.7% of patients, which is very similar to the frequency of this study. 7 Notably, RUNX1 loss in hematopoietic stem cells did not cause AML on its own but established a preleukemic state ❚Figure 2❚ Relapse-free survival of patients with acute myeloid leukemia not otherwise specified according to RUNX1 mutational status (P = .045). 
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AJCP / Original article that predisposed to disease following the acquisition of secondary mutations. 22 The RUNX1 gene is categorized as a class II transcription factor among five classes of leukemogenic genes. 25 It has been hypothesized that the accumulation of several hits in different classes of leukemogenic mutations is one of the critical pathways to leukemia. From a pathogenetic standpoint, it appears reasonable that all coexisting mutations of RUNX1 mutations belong to signaling molecules (class I) or epigenetic regulators (class III) and that RUNX1 mutations are not correlated to other class II mutations such as NPM1 or CEBPA mutations. According to a "slot machine" model for the development of an AML, RUNX1 mutations hold a key position as an initial step paving the way to secondary mutations. 25 Thus, molecular characterization in terms of mutation profiling potentially helps to understand the leukemogenic pathways and modeling that will have a fatal impact on the management of diseases.
The lower platelet count found in patients with RUNX1 mutations in our study was consistent with that of a previous report. 5 Of note, a few characteristics of RUNX1 mutations suggest a role as a poor prognostic factor, including a predominance of older-aged patients, a scarcity of favorable molecular markers such as NPM1 and CEBPA mutations, a lack of favorable cytogenetics, the correlation with adverse cytogenetics such as -5 or -7 in a small subset of patients, and a correlation with secondary AML. [4] [5] [6] [7] [8] [9] However, most previous studies have reported that the RUNX1 mutation was an independent inferior prognostic factor. [4] [5] [6] [7] [8] [9] The present study also demonstrated that patients with RUNX1 mutations had a lower CR rate, a shorter RFS, and a shorter OS, although the difference was marginal compared with patients with the wild-type gene. As our study patients principally belonged to AML NOS, their inferior survival was exclusive of adverse cytogenetics and secondary AML. A previous study displayed a similar scheme to ours: Mendler et al 7 showed that primary AML patients with NK with RUNX1 mutations had lower CR rates, shorter disease-free survival, and shorter OS. Furthermore, they also observed negative outcomes in patients with RUNX1 mutations in both younger (<60 years) and older (≥60 years) age groups. The prognostic value of RUNX1 mutations led this mutation to be integrated into a prognostic model of AML. Grossmann et al 26 proposed a five-category molecular prognostic model, which included very favorable, favorable, intermediate, unfavorable, and very unfavorable. An unfavorable risk was defined as MLL-PTD and/or RUNX1 mutated and/or ASXL1 mutated. NPM1 and CEBPA mutations were detected in 60.2% and 8.6% of patients with NK AML, respectively. 7, 8 We showed that the overall incidence of RUNX1 mutations was 13.4% for patients with NK AML. Therefore, it is certain that a substantial proportion of patients with NK AML with no mutations in NPM1 and CEBPA have RUNX1 mutations. Considering that the WHO revision criteria included "AML with mutated RUNX1" as a provisional entity, 10 it is highly recommended that RUNX1 mutational status should be tested in patients with an intermediate cytogenetic risk and the absence of NPM1 and CEBPA mutations. It is also noteworthy that patients with RUNX1 mutations show a lower frequency of NK and have heterogeneous cytogenetic features, whereas patients with either NPM1 or CEBPA mutations are strongly associated with having NK AML. This suggests that patients with RUNX1 mutations could show a less uniform clinical behavior than patients with either NPM1 or CEBPA mutations. Indeed, a recent study reported that RUNX1 mutations had a favorable prognostic impact in the context of allogeneic hematopoietic cell transplantation. 27 This may suggest a variable degree of prognostic influences in patients with RUNX1 mutations, depending on therapeutic conditions.
Immunophenotypes are often characteristic in specific subtypes of AML. The prototypes include the absence of CD34 and HLA-DR in acute promyelocytic leukemia, the absence of CD34 in AML with mutated NPM1, and the cross-lineage expression of CD19 in AML with RUNX1-RUNX1T1. This study demonstrated that most patients with RUNX1 mutations showed an early hematopoietic progenitor immunophenotype, which may be helpful for predicting the presence of RUNX1 mutations in patients with an intermediate cytogenetic risk or AML NOS.
Unfortunately, we were not able to evaluate the potential impact of the type of RUNX1 mutation on clinical outcomes or perform further analyses incorporating other mutations such as FLT3-ITD, principally due to the low number of patients who had useable and long-term clinical data. However, we have provided useful pathologic information on a new provisional entity of AML with mutated RUNX1 focusing on AML NOS, which is an extremely heterogeneous subgroup of AML. In summary, we detected RUNX1 mutations in 15.1% of patients with AML NOS. Frameshift mutations were most common, and mutations clustered in the RHD. We also identified distinct features of cases with RUNX1 mutations, including a lower platelet count, no co-occurrence of NPM1 and CEBPA mutations, and an early hematopoietic immunophenotype. A review of previous studies demonstrated that patients with RUNX1 mutations are largely confined to an intermediate risk group and have relatively heterogeneous cytogenetic features and coexisting mutations, indicative of a "slot machine" model of leukemogenesis. Since the RUNX1 mutation is generally associated with a poor prognosis for AML NOS, an accurate diagnosis and
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